ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
ImageneBio, Inc. (IMA) - Total Liabilities
Latest total liabilities as of September 2025: $21.05 Million USD
Based on the latest financial reports, ImageneBio, Inc. (IMA) has total liabilities worth $21.05 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ImageneBio, Inc. - Total Liabilities Trend (2018–2024)
This chart illustrates how ImageneBio, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ImageneBio, Inc. Competitors by Total Liabilities
The table below lists competitors of ImageneBio, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Saksiam Leasing Public Company Limited
BK:SAK
|
Thailand | ฿9.23 Billion |
|
Tembo Global Industries Limited
NSE:TEMBO
|
India | ₹4.27 Billion |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
Korea | ₩74.22 Billion |
|
T.K.S. Technologies Public Company Limited
BK:TKS
|
Thailand | ฿1.04 Billion |
|
Cameo Communications Inc
TW:6142
|
Taiwan | NT$1.20 Billion |
|
ReaLy Development & Construction
TWO:2596
|
Taiwan | NT$3.20 Billion |
|
Marie Brizard Wine & Spirits
PA:MBWS
|
France | €65.77 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down ImageneBio, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ImageneBio, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ImageneBio, Inc. (2018–2024)
The table below shows the annual total liabilities of ImageneBio, Inc. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $15.58 Million | -30.26% |
| 2023-12-31 | $22.34 Million | -11.68% |
| 2022-12-31 | $25.29 Million | -36.78% |
| 2021-12-31 | $40.00 Million | -85.15% |
| 2020-12-31 | $269.45 Million | +82.76% |
| 2019-12-31 | $147.44 Million | +121.66% |
| 2018-12-31 | $66.52 Million | -- |